Trastuzumab Biosimilars in the Therapy of Breast Cancer – “Real World” Experiences from four Bavarian University Breast Centres

Introduction With the introduction of the first trastuzumab biosimilar in the summer of 2018, biosimilar antibodies for breast cancer have found their way into the area of gynaecological oncology. The switch of anti-human epidermal growth factor receptor 2 (HER2) therapy from the reference drug Herc...

Descripción completa

Detalles Bibliográficos
Autores principales: Hester, Anna, Gaß, Paul, Fasching, Peter A., Krämer, Anne Katrin, Ettl, Johannes, Diessner, Joachim, Wöckel, Achim, Egger, Tobias, Stock, Katja, Redlin, Jutta, Andraschko, Monika, Harbeck, Nadia, Würstlein, Rachel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467805/
https://www.ncbi.nlm.nih.gov/pubmed/32905322
http://dx.doi.org/10.1055/a-1226-6666

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467805/
https://www.ncbi.nlm.nih.gov/pubmed/32905322
http://dx.doi.org/10.1055/a-1226-6666

Ejemplares similares